Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Invested Capital (2016 - 2025)

Historic Invested Capital for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $598.4 million.

  • Celldex Therapeutics' Invested Capital fell 2386.32% to $598.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.4 million, marking a year-over-year decrease of 2386.32%. This contributed to the annual value of $747.0 million for FY2024, which is 7405.77% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Invested Capital stood at $598.4 million, which was down 2386.32% from $655.4 million recorded in Q2 2025.
  • Celldex Therapeutics' Invested Capital's 5-year high stood at $838.6 million during Q1 2024, with a 5-year trough of $182.3 million in Q2 2021.
  • In the last 5 years, Celldex Therapeutics' Invested Capital had a median value of $419.5 million in 2021 and averaged $477.1 million.
  • In the last 5 years, Celldex Therapeutics' Invested Capital plummeted by 2857.37% in 2023 and then soared by 21854.38% in 2024.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Invested Capital stood at $419.5 million in 2021, then dropped by 22.24% to $326.2 million in 2022, then skyrocketed by 31.57% to $429.2 million in 2023, then soared by 74.06% to $747.0 million in 2024, then fell by 19.9% to $598.4 million in 2025.
  • Its Invested Capital stands at $598.4 million for Q3 2025, versus $655.4 million for Q2 2025 and $703.0 million for Q1 2025.